57 -2 (76) 2025 - Rabbimova N.T., Erkinova N.E. - INDICATORS OF INTRACARDIAL HEMODYNAMICS IN CHRONIC HEART FAILURE WITH VARIOUS COMORBID CONDITIONS

INDICATORS OF INTRACARDIAL HEMODYNAMICS IN CHRONIC HEART FAILURE WITH VARIOUS COMORBID CONDITIONS

Rabbimova N.T. - Samarkand State Medical University Uzbekistan

Erkinova N.E. - Bukhara State Medical Institute named after Abu Ali ibn Sino

Resume

The aim of this study is to investigate the interaction between hyperaldosteronism and kidney fibrosis in patients with chronic heart failure (CHF), as well as to assess the antifibrotic effects of the mineralocorticoid receptor blocker eplerenone and the angiotensin receptor antagonist azilsartan medoxomil. The results showed that these drugs were effective in reducing albuminuria, decreasing fibrosis markers, and lowering inflammatory cytokines. The findings of the study provide an opportunity to develop new therapeutic approaches and effective strategies for treating existing comorbid conditions.

Keywords: CHF (chronic heart failure), hyperaldosteronism, fibrosis, TGF-β1, albuminuria, fibrosis markers, eplerenone, antifibrotic effect, mineralocorticoid receptor blocker, angiotensin receptor antagonist.

First page

307

Last page

310

For citation:Rabbimova N.T., Erkinova N.E. - INDICATORS OF INTRACARDIAL HEMODYNAMICS IN CHRONIC HEART FAILURE WITH VARIOUS COMORBID CONDITIONS//New Day in Medicine 2(76)2025 307-310 https://https://newdayworldmedicine.com/en/new_day_medicine/2-76-2025

List of References

1. Тверская М.С., Ганковская Л.В., Сухопарова В.В., Вирганский А.О. Влияние естественного комплекса цитокинов на структуру и метаболизм проводящей системы сердца в норме и при увеличении гемодинамической нагрузки //Бюллетень экспериментальной биологии и медицины. 2017;164(12):681-685.
2. Шевелёк А.Н. Гиперальдостеронемия как фактор риска почечной дисфункции у больных хронической сердечной недостаточностью с сохраненной фракцией выброса. //Альманах клинической медицины. 2020;48(5):316-324.
3. Шукуров Р.Т., Абдуллаев Т.А. Гендерные различия и коморбидность у больных с ХСН. //Кардиоваскул. терапия и профилактика. 2017;16(6):87-91.
4. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment //Eur. Heart J. 2011;32(6):670-9.
5. Braunwald E. The war against heart failure: the Lancet lecture //Lancet. 2015;385(9970):812-24.
6. Brown N.J., Vaughan D.E., Fogo A.B. Aldosterone and PAI-1: implications for renal injury //J. Nephrol. 2002;15(3):230-235.

   file

   download